Evidence that enhancement of cholinergic tone increases basal plasma levels of calcitonin gene-related peptide in normal man.
To investigate the influence of the cholinergic system on the modulation of the circulating levels of calcitonin gene-related peptide (CGRP) under basal conditions in normal man, the effects of an acetylcholinesterase inhibitor, pyridostigmine bromide, and a muscarinic receptor blocker, pirenzepine, were studied in 16 normal subjects (8 females and 8 males). Pyridostigmine (120 mg, orally) induced a significant (P < 0.01) rise in basal plasma CGRP, while it reduced systolic and diastolic blood pressure. In all subjects, pirenzepine (0.6 mg/kg, i.v. bolus) was unable to modify the basal CGRP level. In conclusion, a pharmacologically induced enhancement of cholinergic tone resulted in an increase in CGRP, whereas muscarinic receptor blockade had no effect on CGRP levels or blood pressure. Therefore, the cholinergic system seems to be involved in the control of CGRP release in man, acting as a positive modulator. However, the available data do not indicate that there is a tonic cholinergic tone responsible for CGRP secretion under physiological conditions.
Trasforini
G
G
Department of Endocrinology, University of Ferrara, Italy.
Margutti
A
A
Vergnani
L
L
Ambrosio
M R
MR
Valentini
A
A
Rossi
R
R
Portaluppi
F
F
Degli Uberti
E C
EC
D000328:Adult; D015740:Calcitonin Gene-Related Peptide / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D009994:Osmolar Concentration; D010275:Parasympathetic Nervous System / Q000187:drug effects / Q000502:physiology*; D010890:Pirenzepine / Q000494:pharmacology; D011729:Pyridostigmine Bromide / Q000494:pharmacology; D012016:Reference Values
D010890:Pirenzepine; D015740:Calcitonin Gene-Related Peptide; D011729:Pyridostigmine Bromide